Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients

Pieter Van Paassen; David Pittrow; Clemens Scheidegger; Jens Klotsche; Pauline M. Ellerbroek

doi:10.2217/imt-2019-0175

Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients

Pieter Van Paassen
, David Pittrow
, Clemens Scheidegger
, Jens Klotsche
, Pauline M. Ellerbroek^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

6 Downloads (Pure)

Abstract

Aim: Data on the real-world use of hyaluronidase-facilitated subcutaneous 10% immunoglobulin (fSCIG; HyQvia^®) in elderly patients with primary or secondary immunodeficiencies (PID or SID) are unreported. This study determined real-world patterns from one administration of fSCIG. Materials & methods: In this retrospective, multicenter study, medical records of patients aged ≥65 years with PID or SID were reviewed. Results: The majority of patients (mean age: 69.9 years) with PID (n = 10) or SID (n = 6) self-administered fSCIG (200-350 ml) at home every 3-4 weeks using a single infusion site by infusion pump at rates up to 300 ml/h. Conclusion: This study provides initial real-world evidence supporting home-based, self-administration of large volumes of fSCIG in elderly patients with PID or SID.

Original language	English
Pages (from-to)	131-139
Number of pages	9
Journal	Immunotherapy
Volume	12
Issue number	2
DOIs	https://doi.org/10.2217/imt-2019-0175
Publication status	Published - Feb 2020

Keywords

elderly patients
fSCIG
home infusion
HyQvia
primary immunodeficiencies
real-world study
recombinant human hyaluronidase-facilitated subcutaneous 10% immunoglobulin
secondary immunodeficiencies

Access to Document

10.2217/imt-2019-0175

imt-2019-0175Final published version, 873 KB

Cite this

@article{1d3429214a8e4311b43162a636292074,

title = "Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients",

abstract = "Aim: Data on the real-world use of hyaluronidase-facilitated subcutaneous 10\% immunoglobulin (fSCIG; HyQvia{\textregistered}) in elderly patients with primary or secondary immunodeficiencies (PID or SID) are unreported. This study determined real-world patterns from one administration of fSCIG. Materials \& methods: In this retrospective, multicenter study, medical records of patients aged ≥65 years with PID or SID were reviewed. Results: The majority of patients (mean age: 69.9 years) with PID (n = 10) or SID (n = 6) self-administered fSCIG (200-350 ml) at home every 3-4 weeks using a single infusion site by infusion pump at rates up to 300 ml/h. Conclusion: This study provides initial real-world evidence supporting home-based, self-administration of large volumes of fSCIG in elderly patients with PID or SID.",

keywords = "elderly patients, fSCIG, home infusion, HyQvia, primary immunodeficiencies, real-world study, recombinant human hyaluronidase-facilitated subcutaneous 10\% immunoglobulin, secondary immunodeficiencies",

author = "Paassen, \{Pieter Van\} and David Pittrow and Clemens Scheidegger and Jens Klotsche and Ellerbroek, \{Pauline M.\}",

note = "Funding Information: V Ruvini Jayasinghe of Oxford PharmaGenesis Inc., Newtown, PA, USA provided editorial assistance, which was funded by Shire Funding Information: This study was funded by Baxalta Innovations GmbH, Vienna, Austria, a member of the Takeda group of companies. P van Paassen received a study grant from Shire, a member of the Takeda group of companies. D Pittrow reports personal fees from Actelion, Bayer, Aspen, Boehringer Ingelheim, Sanofi, Biogen and MSD, outside the submitted work. He has acted as consultant for Baxalta Innovations GmbH, a member of the Takeda group of companies. C Scheidegger has been an investigator of studies funded by Shire, Takeda or Baxalta. J Klotsche reported no conflicts of interest. PM Ellerbroek is a local investigator of studies funded by the Takeda group of companies. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: {\textcopyright} 2020 PM Ellerbroek.",

year = "2020",

month = feb,

doi = "10.2217/imt-2019-0175",

language = "English",

volume = "12",

pages = "131--139",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients

AU - Paassen, Pieter Van

AU - Pittrow, David

AU - Scheidegger, Clemens

AU - Klotsche, Jens

AU - Ellerbroek, Pauline M.

N1 - Funding Information: V Ruvini Jayasinghe of Oxford PharmaGenesis Inc., Newtown, PA, USA provided editorial assistance, which was funded by Shire Funding Information: This study was funded by Baxalta Innovations GmbH, Vienna, Austria, a member of the Takeda group of companies. P van Paassen received a study grant from Shire, a member of the Takeda group of companies. D Pittrow reports personal fees from Actelion, Bayer, Aspen, Boehringer Ingelheim, Sanofi, Biogen and MSD, outside the submitted work. He has acted as consultant for Baxalta Innovations GmbH, a member of the Takeda group of companies. C Scheidegger has been an investigator of studies funded by Shire, Takeda or Baxalta. J Klotsche reported no conflicts of interest. PM Ellerbroek is a local investigator of studies funded by the Takeda group of companies. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: © 2020 PM Ellerbroek.

PY - 2020/2

Y1 - 2020/2

N2 - Aim: Data on the real-world use of hyaluronidase-facilitated subcutaneous 10% immunoglobulin (fSCIG; HyQvia®) in elderly patients with primary or secondary immunodeficiencies (PID or SID) are unreported. This study determined real-world patterns from one administration of fSCIG. Materials & methods: In this retrospective, multicenter study, medical records of patients aged ≥65 years with PID or SID were reviewed. Results: The majority of patients (mean age: 69.9 years) with PID (n = 10) or SID (n = 6) self-administered fSCIG (200-350 ml) at home every 3-4 weeks using a single infusion site by infusion pump at rates up to 300 ml/h. Conclusion: This study provides initial real-world evidence supporting home-based, self-administration of large volumes of fSCIG in elderly patients with PID or SID.

AB - Aim: Data on the real-world use of hyaluronidase-facilitated subcutaneous 10% immunoglobulin (fSCIG; HyQvia®) in elderly patients with primary or secondary immunodeficiencies (PID or SID) are unreported. This study determined real-world patterns from one administration of fSCIG. Materials & methods: In this retrospective, multicenter study, medical records of patients aged ≥65 years with PID or SID were reviewed. Results: The majority of patients (mean age: 69.9 years) with PID (n = 10) or SID (n = 6) self-administered fSCIG (200-350 ml) at home every 3-4 weeks using a single infusion site by infusion pump at rates up to 300 ml/h. Conclusion: This study provides initial real-world evidence supporting home-based, self-administration of large volumes of fSCIG in elderly patients with PID or SID.

KW - elderly patients

KW - fSCIG

KW - home infusion

KW - HyQvia

KW - primary immunodeficiencies

KW - real-world study

KW - recombinant human hyaluronidase-facilitated subcutaneous 10% immunoglobulin

KW - secondary immunodeficiencies

UR - https://www.scopus.com/pages/publications/85079915718

U2 - 10.2217/imt-2019-0175

DO - 10.2217/imt-2019-0175

M3 - Article

C2 - 32066296

AN - SCOPUS:85079915718

SN - 1750-743X

VL - 12

SP - 131

EP - 139

JO - Immunotherapy

JF - Immunotherapy

IS - 2

ER -

Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this